Dillon & Associates Inc Astrazeneca PLC Transaction History

Dillon & Associates Inc

$637 Million
Q1 2024

A detailed history of Dillon & Associates Inc transactions in Astrazeneca PLC stock. As of the latest transaction made, Dillon & Associates Inc holds 24,087 shares of AZN stock, worth $1.85 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

24,087

Previous 23,241 3.64%

Holding current value

$1.85 Million

Previous $1.56 Million 5.2%

% of portfolio

0.26%

Previous 0.28%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$61.03 - $69.57 $51,631 - $58,856	846 Added 3.64%	24,087 $1.64 Million
Q4 2023 Feb 08, 2024	BUY	$61.89 - $69.28 $54,772 - $61,312	885 Added 3.96%	23,241 $1.56 Million
Q3 2023 Nov 13, 2023	BUY	$64.85 - $71.7 $95,653 - $105,757	1,475 Added 7.06%	22,356 $1.52 Million
Q2 2023 Aug 08, 2023	BUY	$69.91 - $75.81 $187,918 - $203,777	2,688 Added 14.77%	20,881 $1.5 Million
Q1 2023 May 02, 2023	BUY	$63.15 - $71.6 $727,993 - $825,404	11,528 Added 172.96%	18,193 $1.26 Million

Q1 2023 May 01, 2023	SELL	$63.15 - $71.6 $611,418 - $693,231	-9,682 Reduced 59.23%	6,665 $462,000
Q4 2022 Feb 06, 2023	BUY	$54.21 - $70.44 $129,941 - $168,844	2,397 Added 17.18%	16,347 $1.11 Million
Q3 2022 Nov 08, 2022	BUY	$53.02 - $135.75 $175,125 - $448,382	3,303 Added 31.02%	13,950 $767,000
Q2 2022 Jul 26, 2022	BUY	$59.26 - $71.14 $109,216 - $131,111	1,843 Added 20.93%	10,647 $703,000
Q1 2022 May 06, 2022	BUY	$55.72 - $67.12 $119,185 - $143,569	2,139 Added 32.09%	8,804 $581,000
Q4 2021 Feb 14, 2022	BUY	$54.02 - $63.83 $360,043 - $425,426	6,665 New	6,665 $387,000

Others Institutions Holding AZN

# of Institutions

1,247

Shares Held

477M

Call Options Held

5.99M

Put Options Held

5.24M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $239B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dillon & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Dillon & Associates Inc with notifications on news.

Account

Dillon & Associates Inc Astrazeneca PLC Transaction History